🇺🇸 Sodium Enoxaparine in United States

7 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 22 April 2025 – 22 April 2026
• Total reports: 7

Most-reported reactions

1. Confusional State — 1 report (14.29%)
2. Cytolytic Hepatitis — 1 report (14.29%)
3. Gait Disturbance — 1 report (14.29%)
4. Hypokalaemia — 1 report (14.29%)
5. Neuralgia — 1 report (14.29%)
6. Pneumonia Aspiration — 1 report (14.29%)
7. Urine Potassium Decreased — 1 report (14.29%)

Source database →

Frequently asked questions

Is Sodium Enoxaparine approved in United States?

Sodium Enoxaparine does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Sodium Enoxaparine in United States?

Biocad is the originator. The local marketing authorisation holder may differ — check the official source linked above.